Compare FSK & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSK | LNTH |
|---|---|---|
| Founded | 2007 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.4B |
| IPO Year | N/A | 2015 |
| Metric | FSK | LNTH |
|---|---|---|
| Price | $14.67 | $66.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $17.33 | ★ $78.00 |
| AVG Volume (30 Days) | ★ 2.9M | 1.2M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | ★ 19.06% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.97 | ★ 2.39 |
| Revenue | ★ $1,578,000,000.00 | $1,525,933,000.00 |
| Revenue This Year | N/A | $0.01 |
| Revenue Next Year | N/A | $1.24 |
| P/E Ratio | ★ $15.13 | $27.55 |
| Revenue Growth | N/A | ★ 1.95 |
| 52 Week Low | $14.05 | $47.25 |
| 52 Week High | $24.10 | $111.29 |
| Indicator | FSK | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 32.76 | 67.34 |
| Support Level | $15.03 | $64.13 |
| Resistance Level | $15.37 | $67.01 |
| Average True Range (ATR) | 0.31 | 2.17 |
| MACD | -0.11 | 0.32 |
| Stochastic Oscillator | 0.79 | 84.68 |
FS KKR Capital Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The company's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation. The company's portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.